INTRODUCTION
Leprosy (or Hansen's disease) is a chronic infection caused by the bacteria Mycobacterium leprae. Identified in 1874 by H. Hansen, it remains one of the most prevalent causes of peripheral neuropathy.
1,2 The diagnosis is achieved through examination of skin lesions or in the presence of multiple mono-neuropathies, sensory and motor peripheral neuropathy, requiring histological confirmation.
Despite a seemingly decreased number of patients, the World Health Organization estimates an annual incidence of 500,000 to 700,000 new patients. The autochthonous Hansen's disease was considered extinct by 2000 in most European countries, except in the South of Italy, Portugal, Spain and Greece. 3 In Portugal, even though it is considered as eradicated (incidence below one patient per 10,000 inhabitants), 31 patients were notified over 2009-2012, only two patients being notified in 2012. The epidemiological variation of this disease in Portugal is characterised by periods of time in which 2 to 3 patients are notified per year, in contrast with other periods in which the incidence increases to 9-16 patients per year (1990-1994 and 2006-2008) 
MATERIAL AND METHODS
The patients with leprosy-related neuropathy diagnosed at the Neuropathology Unit from the Hospital Santo António, Centro Hospitalar do Porto were analysed, in the light of this infrequent condition. This was a retrospective and observational study performed through database and clinical record analysis, considering the patient's age, area of residence, symptoms, duration of disease and neuropathological review of nerve, muscle and/or skin biopsies including a description of the pathological findings.
RESULTS
In total, 21 patients were diagnosed between 1978 and 2013 with leprosy-related neuropathy (13 males). As regards the patient's place of residence, five were from the Trás-osMontes region, three from Minho and 13 from the Douro Litoral. The patient's average age at the time of diagnosis was 52 (18 -76) and in four cases data was unavailable. In the remaining 17 patients, there was on average a 10-year timeframe (1-38 years) between the beginning of symptoms and a definitive diagnosis. In total, 13 cases were diagnosed in the eighties and over the subsequent years a progressive decrease occurred and an event-free 15-year period when no cases were notified (1997 to 2012). Only two patients were identified in 2012 and 2013, both with a previous residence in an endemic country (Brazil). One of these had been treated 20 years before for skin leprosy. In the other 15 patients, only one patient had lived in an endemic country.
Sensory impairment was the symptom more frequently described by 14 patients and four patients had simultaneous motor neuropathy symptoms. Five patients presented with skin lesions.
Glove and stock hypoesthesia was the most frequent finding in the neurological examination (n = 14), with distal motor deficit in four patients. Tuberculoid leprosy was identified by the nerve neuropathological examination in 20 patients ( Fig.s 1 and 2 ) and the lepromatous form was identified in only one patient. Leprosy-suggestive lesions were found in five of the skin biopsies (n = 12), as well as in four of muscle's biopsies (n = 5). The presence of Hansen's bacilli (with the Ziehl-Neelsen's staining technique) was found in the nerve biopsy in 13 patients and four in the skin (44% of nerve and 42% of skin biopsies) and one skin sample was macroscopically normal. Bacilli from the case diagnosed in 2012 were detected with a Fite Faraco stain (Fig. 3) .
DISCUSSION
Mononeuritis is the most common presentation of Hansen's disease 1, 4 and upper limb nerves are the most frequently affected. Skin involvement progresses with disfiguring lesions, responsible for the stigmatizing nature of this disease. Despite the aetiological agent -Mycobacterium leprae -having been identified more than a century ago, little is known about the underlying pathophysiological mechanism responsible for the nerve lesion. 5 The main limitation to research in this area regards obtaining tissue samples to be studied, as a result of its multifocal presentation and wide lesion-free areas of skin. 5 Infection with Mycobacterium leprae damages myelinated and unmyelinated fibres. The bacillus invades the nerve during the infection process with subsequent nerve destruction, producing an immune response promoted by Schwann cells with resulting demyelination, axonal degeneration and subsequent regeneration with fibrosis, enlarged nerves, as a result of which these are usually palpable. Treatment itself may produce an exacerbated inflammatory response with nerve destruction. 6 The type of immune response, mediated by type-II HLA genes will determine whether leprosy will be lepromatous or tuberculoid. In the first form, macrophages do not have the capacity to eliminate the bacilli while in the second the cellular response is so intense that it induces a granulomatous reaction. In the tuberculoid form, the multifocal pattern of dissemination is most common. 6 In lepromatous form, the histological pattern is symmetrical, presenting as a pseudo-polyneuritis, progressing with the typical skin lesions or as an isolated small-fibre neuropathy (10% of the patients). 6 The initial nerve damage is usually a small-fibre neuropathy and subsequently involves wider fibres. The pure motor involvement is a rare manifestation of the disease. The less frequent polyneuropathy involvement mainly progresses to a hypoesthesia for pain and temperature, with deep sensory sparing. This form of presentation, characteristic of the initial stages of the disease, is similar to the diabetic or amyloid polyneuropathy, although tendon reflex preservation in leprous polyneuropathy and the nerve enlargement that occurs in approximately 60% of the patients, marks the distinction from those two other entities (as well as from chronic demyelinating inflammatory polyneuropathy). The nerve block or compression syndromes are more difficult to differentiate clinically, as in the case of elbow ulnar neuropathy. 5 The association with autonomic dysfunction has also been described (impairment in sudomotor and vasomotor function). 4 Leprosy is only diagnosed through the neuropathological examination of skin and/or peripheral nerve lesions. The morphological changes induced by the immune response to the infection can be identified by simple staining methods and subsequent bacilli identification through the Fite Faraco or Ziehl-Neelsen methods. 7 Despite these procedures, the low rate of bacilli detection in the tuberculoid form is explained by the absence of an efficient in vitro culture method 2 and as such it relies solely on a direct staining method. An average 25% percentage of bacilli detection (lower than in our group of patients) and the tuberculoid form (in which bacilli are rarer) is usually the most frequently found in literature. The fact that bacilli can be identified in a macroscopically normal skin sample enhances the importance of clinical suspicion regarding Hansen's disease at the time of the clinical examination and the need for a neuropathological examination of different tissues. The diversity of clinical manifestations may even explain the reason why, on average, there is a 10-year gap between initial symptoms and the definitive diagnosis.
From the patients that were identified, at least to the author's knowledge, only the second-to-last patient represented a relapse. It occurred in a female patient presenting with a neuropathy, considered in remission after having undergone treatment for leprous skin disease 20 years before. As this patient had a tuberculoid form in which the bacillus was identified, it cannot be considered a late relapse as this relates to lepromatous leprosy and to an immune pathological mechanism in reaction to the bacillus' antigen. In general, relapse is frequently associated to noncompliance or even to resistance to treatment, the possibility of re-infection remaining an open-ended question. 4 Leprous neuropathy is the most frequent cause of treatable neuropathy worldwide.
1 Treatment initially used -dapsone monotherapy -progressed with antibiotic resistance that in some countries reached up to 40%. 6 Its association with rifampicin or clofazimine has shown more successful cure rates. Since 1981 the WHO has recommended that multiple therapy should be adequate to eradicate the disease and that the recommended regimen should include dapsone associated to daily clofazimine and monthly single doses of rifampicin for one year in multibacillary forms (more than five skin lesions) or for six months in paucibacillary forms (less than five skin lesions). The association of ofloxacin or minocycline may be successful in resistant cases. Treatment may have to be continued for up to 24 months, depending on clinical severity. Relapse rates are high, between 16 and 39% 5 and may be explained not only by the antibiotic resistance but also by the difficulty in complying with such a long treatment, in the absence of an efficient vaccine to prevent spread of disease.
CONCLUSIONS
Hansen's disease is still a public health issue in tropical regions and, although rare, is still described in Western countries. This clinical series is a reminder that this disease, although being considered as eradicated, is still diagnosed in Portugal and should be recognized as a diagnostic possibility in a patient with a peripheral neuropathy.
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